TYK2-JAK1
TYK2-JAK1
Overview
TYK2-JAK1 refers to a dual-target protein axis involving tyrosine kinase 2 (TYK2) and Janus kinase 1 (JAK1), two closely related members of the Janus kinase family that mediate cytokine receptor signaling. In biomedical research and drug development, this target is most often discussed in the context of small-molecule inhibitors designed to modulate inflammatory and immune pathways by suppressing downstream signaling through STAT proteins and related networks.
Because TYK2 and JAK1 participate in overlapping cytokine-driven pathways, they are relevant to diseases characterized by immune dysregulation, including psoriasis, dermatomyositis, and other inflammatory disorders. Pharmacologic inhibition of this axis is intended to reduce pathological cytokine signaling while preserving enough immune function for clinical tolerability. Recent studies have also linked JAK-family signaling to broader pathway interactions such as mTORC1/2 and JAK2/STAT3 signaling, underscoring the network-level effects of targeting TYK2-JAK1 in inflammatory and proliferative disease settings.
Recent Publications Focus
Below is a summary of the newest research publications targeting TYK2-JAK1 (sorted by publication date).
Recent research highlights TYK2-JAK1 as a versatile therapeutic target with applications across inflammatory, autoimmune, regenerative, and malignant diseases. In dermatomyositis, brepocitinib, a first-in-class, oral, selective TYK2-JAK1 inhibitor that blocks cytokine signaling implicated in the disease, has been evaluated in a phase 3 trial [41910335]. In psoriasis, TYK2 inhibition demonstrates dual therapeutic potential to address both dermatological manifestations and frequently coexisting depressive symptoms through modulation of inflammatory signaling and tryptophan metabolism [41524454]. A sophisticated combination therapy approach for inflammatory skin diseases (psoriasis and atopic dermatitis) employed a pH-responsive hydrogel system co-delivering the JAK1 inhibitor upadacitinib with CCR7-targeting siRNA, which synergistically suppressed JAK-STAT and PI3K/AKT/mTOR pathway signaling, reduced pro-inflammatory cytokines, restored barrier function, and ameliorated lesions in disease models [42237357]. TYK2 inhibition has also been evaluated in systemic lupus erythematosus, where deucravacitinib, a selective TYK2 inhibitor, was studied in the phase 2 PAISLEY SLE trial with mechanistic insights derived from whole blood transcriptome profiling [42115051].
Beyond inflammatory diseases, TYK2-JAK1 targeting has revealed broader therapeutic potential. In regenerative medicine, ruxolitinib conditioning of hESC-derived retinal pigment epithelium transplants attenuates IFN-γ-JAK1 signaling-driven immunogenicity, reducing T/NK-cell infiltration and improving graft survival and visual function in humanized retinal degeneration models without requiring chronic systemic immunosuppression [42309064]. In cancer, filgotinib, a selective JAK1 inhibitor approved for inflammatory diseases, induces apoptosis in colorectal cancer cells through p53 signaling pathway activation, revealing previously unexplored anti-tumor effects [42364020]. For myelofibrosis with splenomegaly and moderate-to-severe anemia, momelotinib, a JAK1/JAK2/ACVR1 inhibitor approved for the disease, has shown clinical benefit in real-world settings after ruxolitinib failure [42118670].
Novel protein degradation platforms are expanding the TYK2-JAK1 therapeutic toolkit. RIMTAC (RIPK1-Mediated Targeting Chimeras) represents an innovative approach to targeted protein degradation that indirectly recruits VHL through hijacking the endogenous RIPK1-VHL complex, with JAK1 among the initial proof-of-concept targets, demonstrating potent, concentration- and time-dependent degradation through a ubiquitin-proteasome system-dependent mechanism that requires a quaternary complex of VHL, RIPK1, the target protein, and the RIMTAC molecule [42417401].